North Chelmsford, MA, United States of America

Roch Boivin

USPTO Granted Patents = 17 (Patent Applications = 2)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 64(Granted Patents)

Location History:

Lawrence, MA (US) (2010 - 2012)
North Chelmsford, MS (US) (2015)
North Chelmsford, MA (US) (2013 - 2023)
Billerica, MA (US) (2023)

Company Filing History:

Eisai R&d Management Co., Ltd.

patents

2 out of 677

Eisai Company, Limited

patents

Years Active: 2010-2023

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11702392 - Pyrimidinone derivatives as SHP2 antagonists (2023-07-18),

2. 11696916 - Carboxamide-pyrimidine derivatives as SHP2 antagonists (2023-07-11),

3. 11542246 - Quinoline compounds as IRAK inhibitors and uses thereof (2023-01-03),

4. 11130758 - Tetrahydropyrazolopyrimidine compounds (2021-09-28),

5. 11033547 - Carboxamide-pyrimidine derivatives as SHP2 antagonists (2021-06-15),

6. 11001561 - Pyrimidinone derivatives as SHP2 antagonists (2021-05-11),

7. 10640500 - Tetrahydropyrazolopyrimidine compounds (2020-05-05),

8. 10233160 - Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors (2019-03-19),

9. 9981925 - Substituted benzo[d][1,2,3]triazines as p70S6K inhibitors (2018-05-29),

10. 9850242 - Tetrahydropyrazolopyrimidine compounds (2017-12-26),

11. 9663486 - Selectively substituted quinoline compounds (2017-05-30),

12. 9446046 - Tetrahydropyrazolopyrimidine compounds (2016-09-20),

13. 9440968 - Substituted pyrido[3,2-d]pyrimidines for treating cancer (2016-09-13),

14. 9126999 - Tetrahydropyrazolopyrimidine compounds (2015-09-08),

15. 8350059 - Intermediates and methods for making zearalenone macrolide analogs (2013-01-08),

Title: Unveiling the Inventive Mind of Roch Boivin

Introduction:

Roch Boivin, a prolific inventor hailing from North Chelmsford, MA, has left an indelible mark on the realm of innovation with his groundbreaking contributions. With a staggering 17 patents to his name, Boivin's inventive spirit has revolutionized the landscape of hyperproliferative disease treatment.

Latest Patents:

Boivin's latest patents showcase his unwavering commitment to advancing medical science. His inventions, such as Pyrimidinone derivatives and Carboxamide-pyrimidine derivatives as SHP2 antagonists, hold immense promise in combatting hyperproliferative diseases in humans. These compounds open new possibilities for pharmaceutical compositions aimed at alleviating the burden of such ailments.

Career Highlights:

Throughout his illustrious career, Boivin has graced the corridors of renowned companies such as Merck Patent GmbH and Eisai R&D Management Co., Ltd. His tenure at these esteemed organizations has been marked by relentless pursuit of innovation and a steadfast dedication to improving healthcare.

Collaborations:

Boivin's collaborative spirit shines through in his partnerships with accomplished coworkers like Theresa L Johnson and Atsushi Endo. Together, they have synergized their expertise to drive forward cutting-edge research initiatives in the domain of hyperproliferative disease therapeutics. It's worth noting that Theresa L Johnson is a woman, adding diversity and unique perspectives to their collaborative efforts.

Conclusion:

In conclusion, Roch Boivin stands as a beacon of innovation, shaping the future of healthcare with his groundbreaking patents and unwavering commitment to scientific advancement. His relentless pursuit of excellence and fruitful collaborations underscore his status as a trailblazer in the field of medical research.

This text is generated by artificial intelligence and may not be accurate.